Rekrutierende Studie = ; Fortlaufende Studie = ; Abgeschlossene Studie = ; Förderung durch ein IRDiRC-Mitglied = ; ERN-Mitglied =

Nationale klinische Studie(n)

FRANKREICH

AUVERGNE-RHONE-ALPES
LYON

Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma (Phase II)

GH Est des HCL - Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)

Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse

Mehr Details

FRANKREICH

ILE-DE-FRANCE
VILLEJUIF

Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years (Phase II)

CLCC Institut Gustave Roussy

Département de Cancérologie de l'enfant et de l'adolescent

Mehr Details

ITALIEN

LOMBARDIA
MILANO

Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia

IRCCS Ospedale San Raffaele

Unità di Ematologia e Trapianto di Midollo Osseo

Mehr Details

ITALIEN

PIEMONTE
TORINO

Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Center Trial

A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette

S.C. di Ematologia

Mehr Details